Notably, preclinical and clinical evidence indicates that DDX5 deficiency in sorafenib-treated HCC cells orchestrates activation of signaling cascades enabling ferroptosis escape [7], a mechanism linked to drug resistance [12, 13]. The gene discussed is DDX5; the disease is hepatocellular carcinoma.